Hemostasis in Liver Cirrhosis and Hepatocellular Cancer
NCT ID: NCT06212635
Last Updated: 2024-01-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
100 participants
OBSERVATIONAL
2022-12-02
2028-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Examination the Ability to Early Diagnose HCC by Combining Three Biomarkers Technology Developed by WAKO, And Their Relevance to Cirrhotic of Patients With Various Backgrounds and the Israeli Population.
NCT02826005
AFP- L3% and DCP as Tumor Markers in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolisation (TACE)
NCT01360255
Dynamic Contrast-enhanced Magnetic Resonance Imaging in Evaluation of Liver Functional Status and Treatment Efficacy in Patients With Hepatocellular Carcinoma After Locoregional Therapy
NCT01281683
Transient Elastography in Hepatectomy for Hepatocellular Carcinoma
NCT01441453
A Cell-free tsRNA Signature for Early Detection of Hepatocellular Carcinoma
NCT07265271
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Non-acute decompensated liver círrhosis
Refractory ascites, low grade encephalopathy but manages to stay at home and only come in ofr check-ups.
T-TAS
Blood test, laboratory assays
Acute decompensated liver cirrhosis
Acute event causing further decompensation and the need for in-patient care
T-TAS
Blood test, laboratory assays
Acute on chronic liver failure
ACLF 1-3 accordic to criterias established through the Cannonic study.
T-TAS
Blood test, laboratory assays
Controls
Healthy individuals
T-TAS
Blood test, laboratory assays
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
T-TAS
Blood test, laboratory assays
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years or older.
* Healthy individuals 18 years or older will serve as controls.
Exclusion Criteria
* Diagnosis of non-cirrhotic coagulopathy, coagulation disorder or thrombophilia prior to inclusion.
* Diagnosis of hematological disease such as hematologic malignancies, non-cirrhotic thrombocytopenia or thrombocytosis, Polycytemia Vera, hemoglobinopathies
* Previous liver transplantation.
* Transfusions the last 7 days.
* Treatment with platelet inhibitors or anticoagulant except for prophylactic dosage of LMWH. If a prophylactic dose of LMWH has been used study sampling with addition of antiFXa must be taken \>12 hours after the last injection.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sahlgrenska University Hospital
OTHER
Region Stockholm
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maria Magnusson, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Region Stockholm, Karolinska Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Karolinska University Hospital
Stockholm, Huddinge, Sweden
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-00316200610
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.